APA (7th ed.) Citation

Pathmanandavel, S., Crumbaker, M., Ho, B., Yam, A. O., Wilson, P., Niman, R., . . . Emmett, L. (2023). Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine, 64(2), 221. https://doi.org/10.2967/jnumed.122.264398

Chicago Style (17th ed.) Citation

Pathmanandavel, Sarennya, et al. "Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)." Journal of Nuclear Medicine 64, no. 2 (2023): 221. https://doi.org/10.2967/jnumed.122.264398.

MLA (9th ed.) Citation

Pathmanandavel, Sarennya, et al. "Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)." Journal of Nuclear Medicine, vol. 64, no. 2, 2023, p. 221, https://doi.org/10.2967/jnumed.122.264398.